Skip to main content
MedPathMedPath Home
Clinical Trials/2024-513708-33-00
2024-513708-33-00
Active, Not Recruiting
Phase 1

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

Sutro Biopharma Inc.9 sites in 3 countries20 target enrollmentNovember 4, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Sutro Biopharma Inc.
Enrollment
20
Locations
9
Status
Active, Not Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
euclinicaltrials.eu
Start Date
November 4, 2024
End Date
TBD
Last Updated
last year
Sex
Female

Investigators

Sponsor
Sutro Biopharma Inc.
Responsible Party
Principal Investigator
Principal Investigator

Director, Clinical Operations

Scientific

Sutro Biopharma Inc.

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Study Sites (9)

Loading locations...

Similar Trials

Recruiting
Phase 1/2
Clinical trial of MDNA11 (investigational drug) administered alone or in combination with pembrolizumab (immune checkpoint inhibitor) in Patients with Advanced Solid Tumors
2023-507536-21-00Medicenna Therapeutics Inc.50
Recruiting
Phase 1
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
NCT07275242Suzhou Suncadia Biopharmaceuticals Co., Ltd.107
Recruiting
Early Phase 1
Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
NCT07291323Janux Therapeutics60
Active, Not Recruiting
Phase 1/2
A Phase 1/2a Study of Safety, Pharmacokinetics and Neutralizing Activity of SPK002 as pre-exposure prophylaxis of COVID-19 in healthy volunteers (Phase 1) and immunocompromised individuals (Phase 2a).
2023-505279-62-00Spikimm78
Recruiting
Phase 1
A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients with MAPK Pathway-driven Advanced Solid Tumors with a Documented RAS, NF1, or RAF Mutation or Patients who have Failed BRAF/MEK Inhibition
2024-510900-34-00Pasithea Therapeutics Corp.24